Application of Cytotoxic T-Lymphocytes for the Treatment of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation.
10.7534/j.issn.1009-2137.2016.02.058
- Author:
Bing-Han ZOU
1
;
Bin ZHANG
1
;
Hu CHEN
1
Author Information
1. Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
- Publication Type:Journal Article
- MeSH:
Adoptive Transfer;
Antigen-Presenting Cells;
cytology;
Cytomegalovirus;
Cytomegalovirus Infections;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Leukocytes, Mononuclear;
cytology;
T-Lymphocytes, Cytotoxic;
cytology
- From:
Journal of Experimental Hematology
2016;24(2):616-621
- CountryChina
- Language:Chinese
-
Abstract:
Human cytomegalovirus (HCMV) infection, a common complication, remains a major risk factor related with patient death after hematopoietic stem cell transplantation (HSCT). Cytotoxic T lymphocytes (CTL) which is crucial to control HCMV infection, can prevent or treat HCMV infection safely and effectively after adoptive infusion. Many studies have been focussed on exploring different methods for preparation of CTL. The method of using antigen presenting cells to stimulate peripheral blood mononuclear cells is simple to operate, easy to conduct large-scale clinical trials. Isolation of CTL from donor-derived PBMC by peptide-tetramer or INF-γ antibody requires a large volume of peripheral blood and high cost for preparation. Third-party CTL can provide an "off-the-shelf" product, but the problem of HLA-mismatch still would be solved. In addition, the clinical efficacy and safety of different methods also vary. This article reviews and compares the current methods to generate CTL and efficacy of the cells after infusions.
